Introduction {#s1}
============

Flaviviruses, a family that includes dengue, tick-borne encephalitis, West Nile, and Zika viruses, are a group of mosquito-borne pathogens of substantial interest for vaccine and small molecule therapeutic development ([@bib4]; [@bib8]). The envelope glycoprotein (E) is the membrane fusogen required for cell entry and infection ([@bib6]). E comprises three beta-sheet rich domains: domain I (DI) is a central beta barrel that organizes the rest of the subunit; domain II (DII: an extension emanating from DI) bears a hydrophobic fusion loop at its distal tip; domain III (DIII), with an immunoglobulin-like fold, connects to the C-terminal 'stem' and transmembrane helical hairpin ([@bib19]). The conserved, fusion-inducing conformational rearrangements these proteins undergo when exposed to reduced pH, from a pre-fusion dimer to a post-fusion trimer, offer an opportunity to exploit the common structural features of all flavivirus E proteins to find viral entry inhibitors ([Figure 1](#fig1){ref-type="fig"}).

![Flavivirus membrane fusion\
(**A**) Steps in the fusion transition. Starting point and end point represent known structures; steps in brackets inferred from experimental evidence as summarized in ([@bib2]). (**B**) Scheme for simulation of fusion reaction. Array of crosses represents a contact zone with 30 monomers.](elife-36461-fig1){#fig1}

In a crystal structure of the dengue serotype 2 E dimer, a molecule of β-octyl glucoside (β-OG), used in the preparation, was present in a pocket between DI and DII ([@bib15]). This pocket closes up during the fusogenic conformational change ([@bib16]), and the observation that a small molecule can bind there suggested that it might be a good target for an entry inhibitor. Indeed, a screen originally designed to detect small molecules that interfere with another step in the conformational transition yielded a series of cyanohydrazone compounds that bind a soluble DI-DII fragment ([@bib20]). These compounds block fusion in vitro and infection in cell culture; they bind the E protein on the virion surface before the virus attaches to a cell. The most potent of them inhibit viral infectivity with IC~90~ values in the single-digit micromolar range ([@bib20]). Recent studies of the effects of mutation on members of several chemically distinct series of inhibitors, including the cyanohydrazones, confirm that the β-OG pocket is indeed their binding site ([@bib3]).

In previous work on the mechanism of membrane fusion by West Nile virus (WNV) E, we used single-particle fusion measurements with WNV virus-like particle (VLPs) to outline steps in the transition leading to membrane merger ([@bib2]). We could interpret the observed, pH-dependent kinetics with a model in which trimerization of E into an extended intermediate, with the three fusion loops inserted into the target membrane, becomes a kinetic bottleneck in progression to hemifusion, because hemifusion requires collapse to the postfusion conformation of at least two *adjacent* trimers in a \~30 monomer contact zone between a virus particle and the membrane with which it is fusing ([Figure 1](#fig1){ref-type="fig"}). Stochastic simulations gave estimates for the rates of various steps. In the present work, we have extended the analysis to all four dengue virus (DV) serotypes, using VLPs as in our studies of WNV fusion. We also use the single-particle approach to examine inhibition by compounds in the cyanohydrazone series and to estimate the number of small-molecule inhibitors per particle needed to block fusion.

Results {#s2}
=======

Single-particle measurement of dengue VLP hemifusion kinetics {#s2-1}
-------------------------------------------------------------

VLPs for the four DV serotypes were prepared by expression in 293 T cells, essentially as described for WNV VLPs ([@bib2]). Expression was at 28°C rather than 37°C, as the latter yielded particles with substantially lower fusion activity. We measured the pH dependence of bulk hemifusion and found sharply sigmoidal curves with inflection pH of 6.1 for the DV4 VLPs and \~5.4 for those of DV1, DV2 and DV3 ([Figure 2A](#fig2){ref-type="fig"}). We used total internal reflection fluorescence microscopy as described previously ([@bib2]; [@bib5]; [@bib9]; [@bib11]) to determine single-particle dwell time distributions for hemifusion at pH 5.5 ([Figure 2B](#fig2){ref-type="fig"}), with dequenching of DiD-labeled VLPs to mark the moment of hemifusion with the supported lipid bilayer. We incorporated into the target bilayer a pseudo-receptor, to uncouple membrane attachment from exposure of the fusion loop triggered by the pH drop. The receptor was either the lectin domain of DC-SIGN-R linked through a histidine tag to a NiNTA-headgroup lipid or a similarly linked, antigen-binding fragment (Fab) from antibody 1AID-2, specific for DV2 domain II ([@bib2]; [@bib13]; [@bib21]). We found no receptor-dependence of hemifusion dwell times; the data shown are with the DC-SIGN-R.

![Fusion measurements.\
(**A**) Fusion (with liposomes, in bulk solution) for VLPs of the four DV serotypes. The fluorescence from membrane-incorporated DiD is shown as a function of pH. Hemifusion (or fusion) at low pH causes dequenching of the VLP-incorporated fluorophore. (**B**) Histograms of single-particle fusion dwell times (between lowering of pH and observed dequenching) at pH 5.5 for each of the four DV serotypes. Curves show fit with a single exponential (DV1, DV2, and DV4) or with a gamma distribution, N = 2 (DV3). (**C**) Results of a simulation with parameters as described in the text. Compare with experimental data for DV2 fusion in the panel immediately above it.](elife-36461-fig2){#fig2}

The dwell-time distributions in [Figure 2B](#fig2){ref-type="fig"} show some differences among the four serotypes. The exponential used to fit the distributions for DV1, DV2 and DV4 VLPs gives an effective rate constant for a first-order 'rate-limiting step'; the best formal fit for DV3 includes two successive or parallel steps. The bulk fusion vs. pH curve is also less sharply sigmoidal than are the others. Although the inflection pH measured in bulk is similar for DV1, DV2 and DV3, the effective first-order rate of fusion for DV1 is slower. We cannot, however, with our current data relate these differences to functional differences among the isolates.

Small-molecule inhibition {#s2-2}
-------------------------

The compound 3-110-22 ([Figure 3](#fig3){ref-type="fig"}) inhibits DV2 infection with IC~90~ of 0.7 μM ([@bib20]). The IC~50~ for DV2 VLP fusion, measured in bulk, was 1--2 μM ([Figure 3A](#fig3){ref-type="fig"}). We used a concentration of 1 μM to study the effect of 3-110-22 on the dwell-time distribution for single-particle fusion at pH 5.5 ([Figure 3B](#fig3){ref-type="fig"}). Comparison of [Figure 3B](#fig3){ref-type="fig"} with the DV2 VLP panel in [Figure 2B](#fig2){ref-type="fig"} shows that presence of the inhibitor has spread the distribution and introduced a clear rise and fall, suggesting that the inhibitor has retarded a step other than the one that is effectively rate-limiting in its absence.

![Inhibition of DV2 VLP fusion by 3-110-22.\
(**A**) Fluorescence dequenching as a function of inhibitor concentration. (**B**) Single-particle dwell-time distribution at pH 5.5 in the presence of 1 μM inhibitor. (**C** and **D**) Inhibition of DV2 VLP fusion by Alexa-555/3-110-22. (**C**) Fluorescence dequenching as a function of inhibitor concentration. Percent dequenching calculated with 100% as DiD dequenching with no added inhibitor and 0% as dequenching with no pH drop. Error bars are SEM, n = 3. (**D**). Single-particle binding intensity for Alexa-555/3-110-22 in the presence of varying molar ratios of underivatized 3-110-22 (none, 1:1, 1:10). Error bars: SEM; n = 373, 370, 382 for the three sets of measurements, respectively.](elife-36461-fig3){#fig3}

To relate single-particle hemifusion dwell-time distribution and small-molecule occupancy, we conjugated a fluorescent probe (Alexa-555) to 3-110-22 at the 4-position of the benzene ring (see Materials and methods). We confirmed that the modified form of the inhibitor was active by recording bulk hemifusion inhibition and found its IC~50~ to be about 10- to 20-fold higher that of the unmodified compound; the strong tendency of these hydrophobic compounds to associate in solution reduces the effective monomer concentration, and the actual difference may be smaller ([Figure 3C](#fig3){ref-type="fig"}). We also showed that 3-110-22 competed for binding with the modified inhibitor, indicating that they both interact at the same site ([Figure 3D](#fig3){ref-type="fig"}).

We incubated DV2 VLPs with 1 μM Alexa-555/3-110-22, removed excess compound with a desalting column ([@bib20]), and measured single-particle hemifusion events. We determined inhibitor occupancy for each particle using a calibrated intensity in the Alexa-555 channel (see Materials and methods) and correlated the occupancy with hemifusion fate of that particle. At pH 5.5 under the conditions of our experiment, the overall yield of hemifusion in the absence of inhibitor was \~25% (i.e. the percent of total particles in the observation field that ultimately fused). Particles with more than about 12 bound inhibitors failed to fuse at all ([Figure 4](#fig4){ref-type="fig"}). We did not detect particles with more than about 60 copies of Alexa-555/33-110-22, showing that binding saturated at an occupancy consistent with a large fraction of 'small VLPs' (\~60 E subunits) in the preparation. Assuming that the contact zone between the particle and the membrane includes about 30 E subunits (i.e. about half a small VLP) and that binding at one site is independent of the occupancy of any other site, then \~6 bound inhibitors in the contact should block fusion completely. The percent of uncleaved prM, estimated from Western blots, was between 10 and 20% for various preparations. Residual uncleaved prM is usually found in a single cluster on virus particles ([@bib18]); it should therefore be absent from the contact zone with the target membrane, to which the prM associated E cannot attach. If there were no binding of the fluorescent inhibitor to prM-associated E, our estimate for the number of bound inhibitors per fully mature particle needed to prevent fusion completely would be about 14, rather than 12, or 7 in the contact zone, rather than 6. Thus, presence of a small fraction of uncleaved prM on the particles in our experiments would have had at most a relatively small effect on our determination of the inhibitory threshold.

![Frequency of hemifusion (measured as DiD fluorescence dequenching) as a function of number of bound Alexa-fluor-555/3-110-22 molecules.\
Histogram shows the number of particles with a particular number of bound fluorescent inhibitor molecules, in bins of five. The number of particles in a bin that proceeded to hemifusion in the time of the experiment is shown as the height of the purple bar; the number of non-fusing particles is the total height of the bar (blue).](elife-36461-fig4){#fig4}

Simulation of DV2 fusion {#s2-3}
------------------------

We modeled the conformational steps preceding hemifusion with a stochastic simulation, structured like the scheme we used for simulations of West Nile virus hemifusion ([Figure 2C](#fig2){ref-type="fig"}) ([@bib2]). A hexagonal array of 30 E protomers represents the contact patch between viral and cell membranes. Each E subunit transits between an inactive state (in a dimer) and an activated monomer, which can trimerize when two other adjacent monomers are activated. Hemifusion occurs upon formation of two adjacent trimers. Dimer pairs are explicitly defined in the simulation, and a cooperativity factor increases the probability of activation when the dimer partner is already activated. The threshold for trimerization was set to pH 5.4, the bulk threshold for hemifusion, based on our previous finding that these two thresholds are the same for WNV ([@bib2]). The assumption of reversibility for the DV2 E dimer-monomer transition comes from dynamic light scattering measurements performed on Kunjin virus ([@bib2]). The DV2 simulation produced a dwell time histogram at pH 5.5 that could be fit with a single exponential decay ([Figure 2C](#fig2){ref-type="fig"}). In our simulation, the yield for particles achieving hemifusion (defined as the total number of fusion events in a time window divided by the total number of identified particles) was \~25%, as observed experimentally.

Discussion {#s3}
==========

The single-particle fusion kinetics for VLPs of all four dengue serotypes are qualitatively similar to those of WNV ([@bib2]). Moreover, explicit simulation of DV2 fusion corresponds to direct experimental observation, for values of the simulation parameters close to those used to fit corresponding data for WNV. The E proteins of WNV and the four serotypes of dengue virus are closely related to each other, and their comparable in vitro fusion properties support the robustness of both our experimental design and our fusion model.

Inhibition of dengue virus fusion by 33-110-22, shown previously in bulk assays, confirms its likely mode of action in blocking infection ([@bib20]). The inhibitor and its analogs bind E on the virion surface before the particle attaches to a cell, at a site on each of the E monomers that closes up during the transition from prefusion dimer to postfusion trimer ([@bib15], [@bib16]; [@bib20]; [@bib3]). The bound molecules appear to fix the E protein in the conformation present in the prefusion dimer, blocking progression along the fusogenic pathway. We have shown that the assay originally used to identify the cyanohydrzone inhibitors probably worked because these molecules lock the hinge in a dimer-like configuration, even in the context of a fusion-intermediate trimer ([@bib12]). Synthesis of a fluorescent derivative has now enabled us to examine its effects on a single-particle basis and hence to derive not only a bulk inhibitory IC~50~ but to determine the fusion efficiency as a function of the number of molecules bound.

Most of the particles in our preparations were small, \~60 subunit VLPs. As we concluded above from the data in [Figure 4](#fig4){ref-type="fig"}, the parameter likely to be relevant to small-molecule inhibition is the number of E proteins in the contact zone between particle and target membrane, estimated here, as in our previous work, as \~30. The experimental results show that about 6--7 inhibited monomers in a 30-monomer contact zone (a fractional occupancy of about 0.2) will be enough to prevent fusion completely (see [Figure 4](#fig4){ref-type="fig"}). Our previous work with WNV VLPs showed that virions, virion-sized (180-subunit) VLPs, and small VLPs have indistinguishable fusion kinetics, including their pH dependence ([@bib2]). Therefore, about 35 inhibitors per dengue virion (i.e. about 20% occupancy) should block any detectable fusion, assuming that for complete inhibition the threshold density of bound inhibitor is the same for the two size classes. An important inference is that complete (or nearly complete) inhibition should occur at concentrations substantially lower than the Kd for an individual binding event.

In the simulation scheme in [Figure 1B](#fig1){ref-type="fig"}, modeling the effect of inhibitor binding to a monomer, at any step in the fusogenic conformational change, by inactivating at random seven monomers does not lead to full inhibition without further restrictions on the model. That is, there are ways of distributing inactivated monomers within the 30-monomer contact zone that still allow two neighboring, activated trimers to form, although in general more slowly than if all monomers could participate (see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We suggest two potential explanations: (i) failure of an inhibitor-free trimer to associate with the target membrane, leading to an abortive fold-back with insertion of the fusion loops into the virion membrane instead; (ii) dimer cooperativity, such that binding of inhibitor to one dimer partner inactivates (with some probability) the other, for example, by inhibiting dimer dissociation, thereby preventing the unliganded partner from forming an active trimer with other neighbors. The former mechanism would add a dead-end side reaction to the trimer zippering step in [Figure 1](#fig1){ref-type="fig"}. It is precisely analogous to the mechanism that accounts for a closely related observation in studies of influenza virus fusion ([@bib10]; [@bib17]). The latter mechanism would generate more effectively inhibited monomers than actual bound inhibitor molecules. Both inspection of diagrams such as the one in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and modified simulations with randomly inactivated monomers in the contact zone show that a total of eight or nine inactive monomers in the contact zone \-- just one or two in addition to the seven with bound inhibitor \-- would be enough to rule out formation of two adjacent, active trimers. Thus, the abortive trimer model would require only a low frequency of dead-end events, with minimal effect on fusion yield or kinetics in the inhibitor-free case (see also the similar conclusion for influenza fusion: [@bib10]), and the dimer cooperativity model would require a relatively low probability for inactivation of the unliganded dimer partner (e.g. only partial inhibition of dimer dissocation). The geometrical idealizations inherent in the current simulation model do not allow us to distinguish between these alternatives.

Materials and methods {#s4}
=====================

Virus-like particles (VLPs) {#s4-1}
---------------------------

Dengue virus-like particles were produced from a stable, mycoplasma-free 293 T cell line (obtained originally from the Broad Institute ([@bib14]), maintained in our laboratories since then, and not further characterized) transfected with the pVRC8400 expression vector bearing a structural cassette containing a codon-optimized version of the prM-E sequence from the DV 1 clone 45AZ5, DV two clone Harvard/BID-V2992/2009, DV three isolate IN/BID-V2417/1984, or DV4 isolate TVP/360. A tissue plasminogen activator signal sequence preceded prM-E. The mycoplamsa-free, adherent cells were grown at 28°C in Gibco FreeStyle 293 medium (Life Technologies, Grand Island, NY). The DV VLPs in the medium were harvested after 2 days, clarified from debris by low-speed centrifugation, and precipitated with polyethylene glycol 8000. Following resuspension in buffer containing 20 mM tricine (N-(2-Hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine) pH 7.8, 140 mM NaCl and 0.005% Pluronic F-127, VLPs were purified over an Optiprep density gradient (SW41 rotor, 34,000 rpm, 4°C, 2 hr. 20 min.) with 55--45−35--30−25−20--10% steps. We collected the band between the 35 and 30% densities and found this material to contain particles 35 and 50 nm in diameter as assessed by cryo- and negative-stain electron microscopy ([@bib1]). The percent of uncleaved prM, estimated from Western blots, was between 10 and 20% for various preparations. Particle membranes were labeled with DiD (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate) at ∼20 μM or 20-fold the protein concentration. Excess dye was removed using NAP-10 desalting column (GE Healthcare, United Kingdom).

Small molecule synthesis {#s4-2}
------------------------

Synthesis of Alexa fluor 555 conjugate began with phenol installation on 3-110-22 at the 4-position of the benzene ring according to the procedure previously reported ([@bib20]). A primary amine with a four-carbon linker was attached to the phenol by etherification and deprotection. Amidation between the primary amine and the commercially available Alexa fluor 555 NHS ester then generated an Alexa fluor 555 conjugated 3-110-22, which was confirmed by ^1^H NMR.

General SI-Chemistry {#s4-3}
--------------------

All reactions were monitored by LC/MS (Waters 2998 Photodiode Array Detector, Waters SQ detector 2, Waters 515 HPLC pump, Waters 2545 Binary Gradient Module, Waters System Fluidics Organizer and Waters 2767 Sample Manager) using a SunFireTM C18 column (4.6 × 50 mm, 5 µm particle size): solvent gradient = 80% A at 0 min, 1% A at 5 min; solvent A = 0.035% TFA in Water; solvent B = 0.035% TFA in MeOH; flow rate: 1.5 mL/min. Reaction products were purified by flash column chromatography using CombiFlashRf with Teledyne Isco RediSepRf High Performance Gold or Silicycle SiliaSepTM High Performance columns (4, 12, 24, 40, or 80 g) and a Waters HPLC system using SunFireTM Prep C18 column (19 × 100 mm, 5 µm particle size): solvent gradient = 80% A at 0 min, 5% A at 25 min; solvent A = 0.035% TFA in water; solvent B = 0.035% TFA in MeOH; flow rate: 25 mL/min. The purity of all compounds was greater than 95% as analyzed by LC/MS (see above). Chemical shifts are reported in parts per million (ppm, δ) downfield from tetramethylsilane (TMS). Coupling constants (*J*) are reported in Hz. Spin multiplicities are described as br (broad), s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet).

![Addition of four-carbon linker with primary amine to 3-110-22](elife-36461-fig5){#C1}

Compound 1 was prepared from 4-amino-2-(trifluoromethyl)phenol as described ([@bib20]). To a solution of compound 1 (250 mg, 0.67 mmol) in *N*,*N*-dimethylformamide (2 mL) were added *tert*-butyl (4-bromobutyl)carbamate (101 mg, 0.40 mmol) and potassium carbonate (139 mg, 1.01 mmol). After stirring at 70°C for 6 hr, the reaction mixture was cooled to room temperature, diluted with EtOAc and washed five times with water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (DCM: MeOH = 90: 10) to afford compound 2 as a yellow solid (200 mg, 91%). m/z: 567.13 \[M + Na\]^+;\ 1^H NMR (600 MHz, CD~3~OD) *δ* 7.92 (s, 1 hr), 7.85--7.82 (m, 1 hr), 7.80 (d, *J* = 7.6 Hz, 1 hr), 7.77--7.73 (m, 1 hr), 7.63 (d, *J* = 8.8 Hz, 1 hr), 7.54 (t, *J* = 7.6 Hz, 1 hr), 7.37 (t, *J* = 7.3 Hz, 1 hr), 7.29 (d, *J* = 9.4 Hz, 1 hr), 4.14 (t, *J* = 6.2 Hz, 2 hr), 3.11 (t, *J* = 6.8 Hz, 2 hr), 1.87--1.81 (m, 2 hr), 1.71--1.64 (m, 2 hr) 1.43 (s, 9 hr).

![Conjugation of Alexa fluor 555 with activated 3-110-22.](elife-36461-fig6){#C2}

Step 1: To a solution of compound 2 (200 mg, 0.37 mmol) in CH~2~Cl~2~ (4 mL) was added trifluoroacetic acid (1 mL). After stirring for 1 hr, the reaction mixture was diluted with CH~2~Cl~2~ and alkalinized with saturated sodium bicarbonate. The organic layer was separated, and the aqueous layer was extracted five times with CH~2~Cl~2~. The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give *N*-Boc deprotected precursor as a yellow oil (152 mg, 92%) m/z: 445.07 \[M + 1\]+.

Step 2: To a solution of compound 2 (2.7 mg, 0.006 mmol) in *N*,*N*-dimethylformamide (0.5 mL) were added DMAP (0.6 mg, 0.0048 mmol) and Alexa fluor 555 NHS ester (ThermoFisher Scientific, m.w. \~1250, 5 mg, 0.004 mmol). The resulting mixture was stirred at room temperature for 3 hr, diluted with DMSO and the product purified by prepHPLC to give compound three as a red solid (m.w. \~1579, 1.5 mg, 24%).

Single particle assay {#s4-4}
---------------------

Single particle data were collected as previously described ([@bib2]). Briefly, glass coverslips were cleaned by sonication in '7X' detergent, 1M potassium hydroxide, acetone and ethanol, and dried for 1 hr at 100°C. Polydimethylsiloxane (PDMS) flow cells with 0.5 mm wide and 70 μm high channels (five per cell) were bonded to plasma-treated glass. Teflon FEP tubing (0.2 mm, Upchurch Scientific) connected an Eppendorf tube with solution to the channel, and Intramedic polyethylene tubing (0.76 mm) connected the channel to a syringe pump (Harvard Pump 11; Harvard Apparatus, Holliston, MA).

Liposomes for preparing planar bilayers contained 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (POPC), cholesterol, and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) (FL-PE) and 1,2-dioleoyl-sn-glycero-3-\[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl\] (Ni-NTA DOGS) (Avanti Polar Lipids, Alabaster, AL) in a ratio of 4:2:2:2:0.02:1%. Liposomes at 10 mg/ml were extruded through a 200 nm pore-size polycarbonate membrane filter. Liposomes were loaded into the flow cell, and the flow stopped to allow bilayers to form. We performed fluorescence recovery after photobleaching experiments to confirm the fluidity of the bilayer. Unattached liposomes were washed away, and 1A1D-2 Fab or the lectin domain of DCSIGN-R, with a C-terminal His6 tag, was introduced at 50 nM for 2 min. 1A1D-2 Fab was produced from a stable 293T line expressing both heavy and light chains from the pVRC8400 vector, purified by Ni-affinity chromatography and S200 size-exclusion chromatography. DCSIGN-R was expressed from Hi-5 cells infected with recombinant baculovirus. Labeled virus particles were loaded onto the pseudo-receptor decorated bilayer. To initiate fusion, we introduced acetate buffer (100 mM sodium acetate, pH 5.0--5.5) or MES (100 mM, pH 5.75--6.25), with 140 mM sodium chloride and 0.005% Pluronic F-127.

Fluorescence measurements {#s4-5}
-------------------------

End-point bulk fusion data were collected using a GE Amersham Typhoon plate reader at 633 and 670 nm excitation and emission wavelengths respectively in 96-well clear-bottom plates with 2 mg/ml final lipid concentration (200 nm liposomes prepared as described above). VLPs were prepared and labeled with DiD as previously described ([@bib2]).

Bulk liposome fusion data were collected on a PTI (Photon technology International, Edison, NJ) 814 Fluorimeter, with 648 and 669 nm excitation and emission wavelengths respectively, using a Cole--Parmer digital polyStat temperature controlled thermo-jacket at 2 Hz over 10 min and at 0.2 mM final lipid concentration (200 nm liposomes prepared as described above).

Single-particle fusion data were collected on an inverted Olympus IX71 fluorescence microscopy with a high numerical aperture objective (60×, N.A. = 1.3). VLPs were illuminated with 488 and 640 nm Coherent (Wilsonville, OR) lasers. A custom-fabricated water-chilled temperature collar (Bioptecs, Butler, PA) was fitted on the objective turret. Each time-lapsed fluorescence video was recorded at 1 Hz for 300 s using 3i Slidebook software. Data were analyzed using Igor and MatLab. IC~50~ was determined by non-linear regression.

The single-fluorophore fluorescence intensity was calibrated by drying buffer containing the labeled small molecule onto a glass slide and monitoring single step photobleaching events under identical imaging conditions as in the experiment.

Competition assay {#s4-6}
-----------------

We used TIRF microscopy, as described ([@bib2]). Coverslips were sonicated in ethanol and water and then glow discharged prior to use. VLPs were dye labeled as in fusion experiments, but at 1:10 the concentration of DiD as we did not require quenching; the concentration of VLPs was five times higher than used for the bulk fusion assay. Labeled VLPs were mixed with 1 μM fluorescent inhibitor for five mins before loading onto the TIRF. For competition assays with unlabeled inhibitor, DiD labeled VLPs were first incubated with the 3-110-22 for 5 mins at 1 or 10 μM, followed by addition of Alexa555/3-110-22 for five mins.

Calcuations were made by densitometry of the VLP spots as identified in ImageJ. The spots were found with the VLP fluorescent channel (DiD) and then both channels were measured, background subtracted, and the ratio of Alexa555 to DiD determined.

Simulations {#s4-7}
-----------

Matlab code, modified from our previous work ([@bib2]), was used with parameters optimized against experimentally measured values for DV2. Code is publicly available at <https://github.com/Harrison-Lab/Flavivirus> ([@bib7]; copy archived at <https://github.com/elifesciences-publications/Flavivirus>).
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Thank you for submitting your article \"How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Randy Schekman as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

In this Research Advance article, Chao et al. extend the work they published in a research article in *eLife* in 2014 on the mechanism and dynamics of membrane fusion of West Nile (WN) virus-like particles to all four dengue virus serotypes. As in the original study, membrane fusion is assayed with liposomes in bulk, in and a single particle assay with a planar lipid bilayer installed in customized microfluidic cells imaged by TIRF microscopy. The 2014 study is extended further with experiments examining the mechanism of inhibition by a small hydrophobic compound, 3-110-22, previously identified as inhibitors of the fusogenic conformational transition in dengue virus. The authors then determined the minimum number of inhibitor molecules per virus like particle (VLP) to completely prevent fusion. The observed minimum number per VLP (15) along with a simulation suggests a model where the inhibitor interferes with the transition from dimer to monomer of the envelope protein.

All referees agree that your study constitutes an interesting extension of your previous work to a medically more relevant virus, confirming that the stochastic simulations developed previously indeed produces meaningful results. Thus, the referees suggest in principle publication provided that the following two issues are addressed during revision:

1\) Most importantly, a possible caveat is that the authors have used 293T cells to produce the VLPs. A previous study reported that dengue virions produced in 293T cells yield near 70% uncleaved prM (Dejnirattisai et al., Nature Immunology 2015), and the presence of prM inactivates its E partner for fusion. In the previous publication on WNV, the authors had explicitly verified that uncleaved prM was only a minimal proportion of the particles. It seems important that they quantify here the amount of uncleaved prM, and if its contribution is important, it would require to explicitly model its presence in their simulations.

2\) Another concern is regarding the location of the 3-110-22 binding site. The authors show that 3-110-22 and the fluorescently labeled analog compete for the same binding site, which is \"presumed\" to be the detergent binding pocket of the E protein. Based on the fusion simulation data and on the maximum number of fluorophore per VLP the compound is proposed to bind to the E protein dimer and inhibit the dimer to monomer transition as opposed to other steps downstream in the fusion reaction. Ultimately, a structure of the bound inhibitor would be of interest, but this is outside the scope of this Research Advance. In the absence of such a structure (or structure/function mutagenesis), a more in depth discussion of the likely binding site and likely mechanism of inhibition would be desirable.
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Author response

> All referees agree that your study constitutes an interesting extension of your previous work to a medically more relevant virus, confirming that the stochastic simulations developed previously indeed produces meaningful results. Thus, the referees suggest in principle publication provided that the following two issues are addressed during revision:
>
> 1\) Most importantly, a possible caveat is that the authors have used 293T cells to produce the VLPs. A previous study reported that dengue virions produced in 293T cells yield near 70% uncleaved prM (Dejnirattisai et al., Nature Immunology 2015), and the presence of prM inactivates its E partner for fusion. In the previous publication on WNV, the authors had explicitly verified that uncleaved prM was only a minimal proportion of the particles. It seems important that they quantify here the amount of uncleaved prM, and if its contribution is important, it would require to explicitly model its presence in their simulations.

Western blots showed that the VLPs used in these studies had (varying among preparations) 10-20% uncleaved prM. As we now state in the Materials and methods section, those particles were harvested from adherent cells after 2 days at 28°C. We found that harvesting after 5 days or switching to suspension culture led to a higher fraction of uncleaved prM, but we have not attempted a systematic study of the variables. The blots (two of which are shown in [Author response image 1](#respfig1){ref-type="fig"}) were from preparations made for the experiments reported.

![Western blots for VLPs of DV1 and DV3.\
A WNV VLP control is on the left. These are photographed from a lab notebook, hence the rulings in the background.](elife-36461-resp-fig1){#respfig1}

> 2\) Another concern is regarding the location of the 3-110-22 binding site. The authors show that 3-110-22 and the fluorescently labeled analog compete for the same binding site, which is \"presumed\" to be the detergent binding pocket of the E protein. Based on the fusion simulation data and on the maximum number of fluorophore per VLP the compound is proposed to bind to the E protein dimer and inhibit the dimer to monomer transition as opposed to other steps downstream in the fusion reaction. Ultimately, a structure of the bound inhibitor would be of interest, but this is outside the scope of this Research Advance. In the absence of such a structure (or structure/function mutagenesis), a more in depth discussion of the likely binding site and likely mechanism of inhibition would be desirable.

A paper (from several of the co-authors of this manuscript) has now been accepted (at Cell Chem Biol) confirming, with mutation and with crosslinking studies (of a member of another series of compounds that competes with 3-110-22), that the binding site is indeed the β-OG pocket. We have cited this paper (in press) in the Introduction, and modified the final paragraph to discuss further its relevance to the data in our current manuscript.

[^1]: Department of Molecular Biology, Massachusetts General Hospital, Boston, United States.

[^2]: Department of Genetics, Harvard Medical School, Boston, United States.
